Today: 14 June 2026
Browse Category

NYSE:BHVN 13 August 2025 - 3 November 2025

Biohaven Stock’s Wild Ride: Big Drops, Big Hopes as FDA Verdict Nears

Biohaven Stock’s Wild Ride: Big Drops, Big Hopes as FDA Verdict Nears

Biohaven Ltd. shares dropped over 20% in pre-market trading Nov. 3, falling to about $13.40 after closing at $17.20 on Oct. 31. The decline comes ahead of an FDA decision on troriluzole, expected in Q4 2025. The stock is down roughly 66% year-over-year, far underperforming biotech peers. Biohaven reported $408 million in cash mid-2025 but posted a $198 million net loss in Q2.
3 November 2025
·
Breakthrough Drug Approved, Billion-Dollar Deals & Outbreak Alerts – Global Biotech & Health Roundup (Aug 12–13, 2025)

Breakthrough Drug Approved, Billion-Dollar Deals & Outbreak Alerts – Global Biotech & Health Roundup (Aug 12–13, 2025)

The FDA approved brensocatib (Brinsupri) as the first treatment for non-cystic fibrosis bronchiectasis, affecting about 500,000 Americans. Novartis reported positive Phase 3 results for ianalumab in Sjögren’s syndrome and immune thrombocytopenia. Biohaven’s OCD drug troriluzole failed in late-stage trials. Cardinal Health will acquire Solaris Health for $1.9 billion in cash.
13 August 2025
···

Stock Market Today

  • GHCL Limited to Trade Ex-Dividend on June 18 with ₹12 Dividend Payment
    June 13, 2026, 11:31 PM EDT. GHCL Limited (NSE:GHCL) will trade ex-dividend on June 18, meaning shareholders must purchase shares before this date to qualify for the upcoming dividend payout of ₹12 per share on July 25. The stock currently trades at ₹430.45, offering a trailing dividend yield of approximately 2.8%. GHCL's dividend payout ratio is conservatively low at 24% of its profit after tax and covers just 27% of its free cash flow, indicating sustainable dividend payments. Additionally, the company has demonstrated a 10% average annual growth in earnings per share over the past five years, supporting future dividend increases and business growth.

Latest articles

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

14 June 2026
Kraft Heinz closed up 0.70% at $24.39, outpacing the S&P 500, as investors weighed its 6.6% dividend yield against falling organic sales, lower adjusted earnings, and cautious analyst targets; the next earnings update is seen as the key test for whether $600 million in marketing and R&D can revive growth and support the stock’s rebound.
Go toTop